Parkinson'
Conditions
Interventions
None listed
Sponsors
National Institutes for Quantum Science and Technology
Biogen MA Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: <Cross-sectional study> Healthy volunteers who have participated in the following existing studies conducted by QST since February 2017, and who have undergone testing by December 31, 2019. 1) Investigation for efficacy and safety of tau PET ligand [18F]PM-PBB3 (Research Protocol No. 16-036) 2) Tau PET imaging in patients with schizophrenia and patients with frontotemporal dementia (No. 16-037) 3) PET study of central PDE10A density and tau deposition in bipolar disorder. (No. 17-027) <Longitudinal study> Healthy volunteers, patients with Parkinson's disease, and patients with progressive supranuclear palsy spectrum among the study subjects who participated in the following existing studies conducted at QST after November 2017. Mapping of brain tau deposition in tauopathy by PET with [18F]PM-PBB3 (No. 17-034)
Exclusion criteria
Exclusion criteria: (1) Cases in which the research subject or his/her representative refuses the secondary use of data for other research when the existing research is explained. (2) Cases in which the research subject or his/her representative refuses the use of the data for this research at the time the data is shared with the collaborating research organization. (3) Cases in which there is missing data that may affect data analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relationship between [18F]PM-PBB3([18F]APN-1607) PET changes over time and clinical symptoms | — |
Countries
Japan,Asia(except Japan),North America
Contacts
Public ContactShizuko Kawakami
National Institutes for Quantum and Radiological Science and Technology Clinical Research Support Section
Outcome results
None listed